- Home
- USIO vs GNTA Comparison
USIO vs GNTA Comparison
Compare USIO & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | GNTA |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | Italy |
| Employees | N/A | 13 |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.0M | 19.9M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | USIO | GNTA |
|---|---|---|
| Price | $1.24 | $0.72 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 45.2K | ★ 68.8K |
| Earning Date | 05-13-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,200,535.00 | N/A |
| Revenue This Year | $12.25 | N/A |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $0.59 |
| 52 Week High | $2.02 | $10.00 |
Technical Indicators
Market Signals| Indicator | USIO | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 47.47 |
| Support Level | $1.03 | $0.71 |
| Resistance Level | $1.25 | $0.75 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 84.38 | 38.37 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.